<DOC>
	<DOCNO>NCT00105144</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness two dose level micafungin versus caspofungin treatment proven invasive candidiasis candidemia .</brief_summary>
	<brief_title>Study Micafungin Patients With Invasive Candidiasis Candidemia</brief_title>
	<detailed_description>The purpose study determine efficacy safety two dose level micafungin versus caspofungin treatment proven invasive candidiasis candidemia . The maximum length antifungal treatment 4 week except pre-defined patient maximum length therapy 8 week . A post treatment assessment conduct 2 week 6 week last dose antifungal treatment .</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidemia</mesh_term>
	<mesh_term>Candidiasis , Invasive</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<criteria>Patients must candidemia invasive candidiasis . Patients receive echinocandin within one month prior study entry . Patients receive two day prior systemic antifungal therapy current infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Treatment Effectiveness</keyword>
	<keyword>Treatment Efficacy</keyword>
	<keyword>Investigational , Therapies</keyword>
	<keyword>Antifungal , Systemic</keyword>
	<keyword>Antibiotics , Antifungal</keyword>
	<keyword>Micafungin</keyword>
</DOC>